Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine

John W. Denninger, George I. Papakostas, Yasmin Mahal, Wendelien Merens, Jonathan E. Alpert, Andrew A. Nierenberg, Albert Yeung, Maurizio Fava

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Among patients with major depressive disorder (MDD), physical and somatic symptoms are associated with a high degree of disability and healthcare utilization. However, little is known regarding the treatment of these symptoms with standard pharmacotherapy. To measure somatic symptoms of depression, the authors administered The Symptom Questionnaire (Kellner) before and after 8 weeks of open-label treatment with fluoxetine, 20 mg/day, in 170 MDD outpatients (mean age: 40.4 years). Somatic symptom scores decreased significantly after fluoxetine treatment. The degree of reduction in somatic symptoms was significantly and positively correlated with the degree of improvement in depressive symptoms as measured by the 17-item Hamilton Rating Scale for Depression (Ham-D). Somatic symptom scores at baseline did not predict the degree of reduction in Ham-D scores during treatment. However, fluoxetine-remitters had significantly lower somatic symptom scores at end-point than responders who did not remit. Taken together, these findings suggest that developing treatment strategies that successfully target somatic symptoms of depression may further improve the ability to treat depression to remission.

Original languageEnglish (US)
Pages (from-to)348-352
Number of pages5
JournalPsychosomatics
Volume47
Issue number4
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Fluoxetine
Major Depressive Disorder
Outpatients
Depression
Therapeutics
Aptitude
Medically Unexplained Symptoms
Delivery of Health Care
Drug Therapy

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Applied Psychology
  • Psychiatry and Mental health

Cite this

Denninger, J. W., Papakostas, G. I., Mahal, Y., Merens, W., Alpert, J. E., Nierenberg, A. A., ... Fava, M. (2006). Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. Psychosomatics, 47(4), 348-352. https://doi.org/10.1176/appi.psy.47.4.348

Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. / Denninger, John W.; Papakostas, George I.; Mahal, Yasmin; Merens, Wendelien; Alpert, Jonathan E.; Nierenberg, Andrew A.; Yeung, Albert; Fava, Maurizio.

In: Psychosomatics, Vol. 47, No. 4, 08.2006, p. 348-352.

Research output: Contribution to journalArticle

Denninger, JW, Papakostas, GI, Mahal, Y, Merens, W, Alpert, JE, Nierenberg, AA, Yeung, A & Fava, M 2006, 'Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine', Psychosomatics, vol. 47, no. 4, pp. 348-352. https://doi.org/10.1176/appi.psy.47.4.348
Denninger, John W. ; Papakostas, George I. ; Mahal, Yasmin ; Merens, Wendelien ; Alpert, Jonathan E. ; Nierenberg, Andrew A. ; Yeung, Albert ; Fava, Maurizio. / Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. In: Psychosomatics. 2006 ; Vol. 47, No. 4. pp. 348-352.
@article{6dd9fe4b8e714e179c73e1d9c4689e80,
title = "Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine",
abstract = "Among patients with major depressive disorder (MDD), physical and somatic symptoms are associated with a high degree of disability and healthcare utilization. However, little is known regarding the treatment of these symptoms with standard pharmacotherapy. To measure somatic symptoms of depression, the authors administered The Symptom Questionnaire (Kellner) before and after 8 weeks of open-label treatment with fluoxetine, 20 mg/day, in 170 MDD outpatients (mean age: 40.4 years). Somatic symptom scores decreased significantly after fluoxetine treatment. The degree of reduction in somatic symptoms was significantly and positively correlated with the degree of improvement in depressive symptoms as measured by the 17-item Hamilton Rating Scale for Depression (Ham-D). Somatic symptom scores at baseline did not predict the degree of reduction in Ham-D scores during treatment. However, fluoxetine-remitters had significantly lower somatic symptom scores at end-point than responders who did not remit. Taken together, these findings suggest that developing treatment strategies that successfully target somatic symptoms of depression may further improve the ability to treat depression to remission.",
author = "Denninger, {John W.} and Papakostas, {George I.} and Yasmin Mahal and Wendelien Merens and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Albert Yeung and Maurizio Fava",
year = "2006",
month = "8",
doi = "10.1176/appi.psy.47.4.348",
language = "English (US)",
volume = "47",
pages = "348--352",
journal = "Psychosomatics",
issn = "0033-3182",
publisher = "American Psychiatric Publishing Inc.",
number = "4",

}

TY - JOUR

T1 - Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine

AU - Denninger, John W.

AU - Papakostas, George I.

AU - Mahal, Yasmin

AU - Merens, Wendelien

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Yeung, Albert

AU - Fava, Maurizio

PY - 2006/8

Y1 - 2006/8

N2 - Among patients with major depressive disorder (MDD), physical and somatic symptoms are associated with a high degree of disability and healthcare utilization. However, little is known regarding the treatment of these symptoms with standard pharmacotherapy. To measure somatic symptoms of depression, the authors administered The Symptom Questionnaire (Kellner) before and after 8 weeks of open-label treatment with fluoxetine, 20 mg/day, in 170 MDD outpatients (mean age: 40.4 years). Somatic symptom scores decreased significantly after fluoxetine treatment. The degree of reduction in somatic symptoms was significantly and positively correlated with the degree of improvement in depressive symptoms as measured by the 17-item Hamilton Rating Scale for Depression (Ham-D). Somatic symptom scores at baseline did not predict the degree of reduction in Ham-D scores during treatment. However, fluoxetine-remitters had significantly lower somatic symptom scores at end-point than responders who did not remit. Taken together, these findings suggest that developing treatment strategies that successfully target somatic symptoms of depression may further improve the ability to treat depression to remission.

AB - Among patients with major depressive disorder (MDD), physical and somatic symptoms are associated with a high degree of disability and healthcare utilization. However, little is known regarding the treatment of these symptoms with standard pharmacotherapy. To measure somatic symptoms of depression, the authors administered The Symptom Questionnaire (Kellner) before and after 8 weeks of open-label treatment with fluoxetine, 20 mg/day, in 170 MDD outpatients (mean age: 40.4 years). Somatic symptom scores decreased significantly after fluoxetine treatment. The degree of reduction in somatic symptoms was significantly and positively correlated with the degree of improvement in depressive symptoms as measured by the 17-item Hamilton Rating Scale for Depression (Ham-D). Somatic symptom scores at baseline did not predict the degree of reduction in Ham-D scores during treatment. However, fluoxetine-remitters had significantly lower somatic symptom scores at end-point than responders who did not remit. Taken together, these findings suggest that developing treatment strategies that successfully target somatic symptoms of depression may further improve the ability to treat depression to remission.

UR - http://www.scopus.com/inward/record.url?scp=33747105945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747105945&partnerID=8YFLogxK

U2 - 10.1176/appi.psy.47.4.348

DO - 10.1176/appi.psy.47.4.348

M3 - Article

VL - 47

SP - 348

EP - 352

JO - Psychosomatics

JF - Psychosomatics

SN - 0033-3182

IS - 4

ER -